angelfish therapy, LLC

p.o. box 183
botsford, connecticut 06404

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 01, 2013

NYS DOS ID#
4439261

County
WESTCHESTER

Jurisdiction
CONNECTICUT

Registered Agent
NONE

NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY

Name History
2013 - ANGELFISH THERAPY, LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy VC, Deals, & Startups Feed
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Mt. Sinai's new therapy dog is a mutt with a mission
    By Peter D'Amato - Thursday Aug 10, 2017

    Midway through his shift at Mount Sinai’s Kravis Children’s Hospital, the health system’s youngest worker was doing his rounds—on four legs. Professor Bunsen...

    To view the full story, click the title link.

    Source: Crain&apso;s New York Business
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York